{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:46:58Z","timestamp":1781790418080,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As new migraine therapies emerge, it is crucial for measures to capture the complexities of health-related quality of life (HRQoL) improvement beyond improvements in monthly migraine day (MMD) reduction. Investigations into the correlations between MMD reduction, symptom management, and HRQoL are lacking, particularly those that focus on improvements in canonical symptoms and improvement in patient-identified most-bothersome symptoms (PI-MBS), in patients treated with eptinezumab. This exploratory analysis identified efficacy measures mediating the effect of eptinezumab on HRQoL improvements in patients with migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from the DELIVER study of patients with 2\u20134 prior preventive migraine treatment failures (NCT04418765) were inputted to two structural equation models describing sources of HRQoL improvement via Migraine-Specific Quality-of-Life Questionnaire (MSQ) scores. A single latent variable was defined to represent HRQoL and describe the sources of HRQoL in DELIVER. One model included all migraine symptoms while the second model included the PI-MBS as the only migraine symptom. Mediating variables capturing different aspects of efficacy included MMDs, other canonical symptoms, and PI-MBS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the first model, reductions in MMDs and other canonical symptoms accounted for 35% (standardized effect size [SES] \u2212\u20090.11) and 25% (SES \u2212\u20090.08) of HRQoL improvement, respectively, with 41% (SES \u2212\u20090.13) of improvement comprising \u201cdirect treatment effect,\u201d i.e., unexplained by mediators. In the second model, substantial HRQoL improvement with eptinezumab (86%; SES \u2212\u20090.26) is due to MMD reduction (17%; SES \u2212\u20090.05) and change in PI-MBS (69%; SES \u2212\u20090.21).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Improvements in HRQoL experienced by patients treated with eptinezumab can be substantially explained by its effect on migraine frequency and PI-MBS. Therefore, in addition to MMD reduction, healthcare providers should discuss PI-MBS improvements, since this may impact HRQoL. Health technology policymakers should consider implications of these findings in economic evaluation, as they point to alternative measurement of quality-adjusted life years to capture fully treatment benefits in cost-utility analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p> ClinicalTrials.gov (Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04418765\">NCT04418765<\/jats:ext-link>; EudraCT (Identifier: 2019\u2013004497-25; URL: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-004497-25\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-004497-25<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01752-z","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:02:12Z","timestamp":1711627332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab"],"prefix":"10.1186","volume":"25","author":[{"given":"Linus","family":"J\u00f6nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane A.","family":"Regnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Talon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kymes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"1","key":"1752_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"issue":"1","key":"1752_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"issue":"8","key":"1752_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM, Lipton RB (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache"},{"issue":"1","key":"1752_CR4","doi-asserted-by":"publisher","first-page":"s21","DOI":"10.1007\/s101940170004","volume":"2","author":"G Apolone","year":"2001","unstructured":"Apolone G, Mosconi P (2001) Health\u2013related quality of life (HRQOL) and migraine. J Headache Pain 2(1):s21\u2013s24. https:\/\/doi.org\/10.1007\/s101940170004","journal-title":"J Headache Pain"},{"issue":"6","key":"1752_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1468-2982.2003.00546.x","volume":"23","author":"RB Lipton","year":"2003","unstructured":"Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF (2003) Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 23(6):441\u2013450. https:\/\/doi.org\/10.1046\/j.1468-2982.2003.00546.x","journal-title":"Cephalalgia"},{"issue":"10","key":"1752_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek T, Martinelli D, Terwindt GM (2020) Guidelines of the international headache society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40(10):1026\u20131044. https:\/\/doi.org\/10.1177\/0333102420941839","journal-title":"Cephalalgia"},{"issue":"5","key":"1752_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ (2018) Guidelines of the international headache society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5):815\u2013832. https:\/\/doi.org\/10.1177\/0333102418758283","journal-title":"Cephalalgia"},{"issue":"3","key":"1752_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2011","unstructured":"Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M (2011) Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache 52(3):409\u2013421. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01997.x","journal-title":"Headache"},{"issue":"1","key":"1752_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/head.13701","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Gwaltney C, Kassel E, Snapinn S, Cady R (2020) Content validity of HIT-6 as a measure of headache impact in people with migraine: a narrative review. Headache 60(1):28\u201339. https:\/\/doi.org\/10.1111\/head.13701","journal-title":"Headache"},{"issue":"7","key":"1752_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1526-4610.2006.00444.x","volume":"46","author":"L Kelman","year":"2006","unstructured":"Kelman L (2006) Migraine changes with age: IMPACT on migraine classification. Headache 46(7):1161\u20131171. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00444.x","journal-title":"Headache"},{"issue":"12","key":"1752_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan N, Goadsby PJ (2018) Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 14(12):699\u2013710. https:\/\/doi.org\/10.1038\/s41582-018-0098-4","journal-title":"Nat Rev Neurol"},{"issue":"13","key":"1752_CR12","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine. PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"5","key":"1752_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R (2021) Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache 61(5):766\u2013776. https:\/\/doi.org\/10.1111\/head.14120","journal-title":"Headache"},{"issue":"1","key":"1752_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"issue":"7","key":"1752_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607","journal-title":"Lancet Neurol"},{"issue":"1","key":"1752_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/jpet.119.264671","volume":"374","author":"L Garcia-Martinez","year":"2020","unstructured":"Garcia-Martinez L, Raport C, Ojala E, Dutzar B, Anderson K, Stewart E, Kovacevich B, Baker B, Billgren J, Scalley-Kim M, Karasek C, Allison D, Latham J (2020) Pharmacologic characterization of ALD403, a potent neutralizing humanized monoclonal antibody against the calcitonin gene-related peptide. J Pharmacol Exp Ther 374(1):93\u2013103","journal-title":"J Pharmacol Exp Ther"},{"key":"1752_CR17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/ene.15670","volume":"30","author":"PJ Goadsby","year":"2023","unstructured":"Goadsby PJ, Barbanti P, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B (2023) Eptinezimab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures. Eur J Neurol 30:1089\u20131098. https:\/\/doi.org\/10.1111\/ene.15670","journal-title":"Eur J Neurol"},{"key":"1752_CR18","doi-asserted-by":"publisher","first-page":"15215","DOI":"10.1016\/B0-08-043076-7\/00776-2","volume-title":"International encyclopedia of the Social & Behavioral Sciences","author":"D Kaplan","year":"2001","unstructured":"Kaplan D (2001) Structural equation modeling. In: Smelser NJ, Baltes PB (eds) International encyclopedia of the Social & Behavioral Sciences. Pergamon, Oxford, pp 15215\u201315222. https:\/\/doi.org\/10.1016\/B0-08-043076-7\/00776-2"},{"key":"1752_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-1-61779-555-8_27","volume":"850","author":"CM Stein","year":"2012","unstructured":"Stein CM, Morris NJ, Nock NL (2012) Structural equation modeling. Methods Mol Biol 850:495\u2013512. https:\/\/doi.org\/10.1007\/978-1-61779-555-8_27","journal-title":"Methods Mol Biol"},{"issue":"6","key":"1752_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/13696998.2018.1560304","volume":"22","author":"SP McKenna","year":"2019","unstructured":"McKenna SP, Heaney A, Wilburn J (2019) Measurement of patient-reported outcomes. 2: are current measures failing us? J Med Econ 22(6):523\u2013530. https:\/\/doi.org\/10.1080\/13696998.2018.1560304","journal-title":"J Med Econ"},{"issue":"1","key":"1752_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"H Lt","year":"1999","unstructured":"Lt H, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1\u201355. https:\/\/doi.org\/10.1080\/10705519909540118","journal-title":"Struct Equ Model Multidiscip J"},{"issue":"1","key":"1752_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1129-2377-15-68","volume":"15","author":"SY Kim","year":"2014","unstructured":"Kim SY, Park SP (2014) The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. J Headache Pain 15(1):68. https:\/\/doi.org\/10.1186\/1129-2377-15-68","journal-title":"J Headache Pain"},{"issue":"1","key":"1752_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40359-023-01053-1","volume":"11","author":"M Yousefi Afrashteh","year":"2023","unstructured":"Yousefi Afrashteh M, Abbasi M, Abbasi M (2023) The relationship between meaning of life, perceived social support, spiritual well-being and pain catastrophizing with quality of life in migraine patients: the mediating role of pain self-efficacy. BMC Psychol 11(1):17. https:\/\/doi.org\/10.1186\/s40359-023-01053-1","journal-title":"BMC Psychol"},{"issue":"1","key":"1752_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41598-020-80094-7","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim S, Bae DW, Park SG, Park JW (2021) The impact of pain-related emotions on migraine. Sci Rep 11(1):577. https:\/\/doi.org\/10.1038\/s41598-020-80094-7","journal-title":"Sci Rep"},{"issue":"8","key":"1752_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1080\/13696998.2020.1754840","volume":"23","author":"R Mahon","year":"2020","unstructured":"Mahon R, Huels J, Hacking V, Cooney P, Danyliv A, Vudumula U, Vadapalle S, Vo P, Maniyar F, Palmer S, Goadsby P (2020) Economic evaluations in migraine: systematic literature review and a novel approach. J Med Econ 23(8):864\u2013876. https:\/\/doi.org\/10.1080\/13696998.2020.1754840","journal-title":"J Med Econ"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01752-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:02:14Z","timestamp":1711627334000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01752-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1752"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01752-z","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved at each study site by the corresponding ethics committee or institutional review board. All clinical work was conducted in compliance with current Good Clinical Practices as defined in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines, local regulatory requirements, and the Declaration of Helsinki policy statement. All patients enrolled in the trial provided written informed consent prior to trial participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Linus J\u00f6nsson has received consultancy fees from H. Lundbeck A\/S. Susanne F. Awad, Stephane A. Regnier, Brian Talon, and Xin Ying Lee are employees of H. Lundbeck A\/S. Stephane A. Regnier owns stock or stock options in Novartis. Steven Kymes was an employee of H. Lundbeck A\/S at the time of study and is currently an employee of Ionis Pharmaceuticals. Peter J. Goadsby reports, over the last 36\u2009months, a grant from Celgene, and personal fees from Aeon Biopharma, Allergan\/AbbVie, CoolTech LLC, Dr. Reddy\u2019s, Eli Lilly, Epalex, Impel Neuropharma, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Teva Pharmaceuticals, and Tremeau. He also reports personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, and Vector Metric; fees for educational materials from CME Outfitters, and WebMD; publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UpToDate, and Wolters Kluwer; fees for medicolegal advice in headache; and a patent for magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}